We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Partial responses to ibrutinib in Waldenström macroglobulinaemia ‐ good enough?
- Authors
Vitolo, Umberto; Novo, Mattia; Santambrogio, Elisa
- Abstract
Keywords: Waldenstrom macroglobulinemia; BTK inhibitors; ibrutinib; response; progression-free survival EN Waldenstrom macroglobulinemia BTK inhibitors ibrutinib response progression-free survival 423 424 2 02/02/21 20210201 NES 210201 The B-cell receptor and Bruton tyrosine kinase (BTK) play a fundamental role in the proliferation of B-cell neoplasia such as Waldenström macroglobulinaemia (WM). In WM, ibrutinib, a first-generation BTK inhibitor (BTK-i) has obtained high rates of response and progression-free survival (PFS), both in untreated and rituximab-refractory disease. A Phase II trial of 63 patients with relapsed/refractory (R/R) WM demonstrated an overall response rate (ORR) of 91% and a 2-year PFS of 69-1%.1 Similar results were observed in treatment-naïve patients, with an ORR of 100% and 18-month PFS of 92%.2 Based on these data, ibrutinib has been approved for symptomatic WM.
- Subjects
IMMUNOGLOBULIN M; MEDICAL personnel
- Publication
British Journal of Haematology, 2021, Vol 192, Issue 3, p423
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.17228